1. Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs.
- Author
-
Nørgaard JM, Langkjer ST, Ellegaard J, Palshof T, Clausen N, and Hokland P
- Subjects
- Aclarubicin administration & dosage, Aclarubicin toxicity, Acute Disease, Adult, Aged, Aged, 80 and over, Cell Death drug effects, Coloring Agents, Cytarabine administration & dosage, Cytarabine toxicity, Daunorubicin toxicity, Drug Antagonism, Drug Screening Assays, Antitumor methods, Drug Synergism, Female, Humans, Leukemia, Myeloid pathology, Male, Middle Aged, Prospective Studies, Remission Induction, Antineoplastic Agents toxicity, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Survival drug effects, Cytarabine therapeutic use, Granulocyte Colony-Stimulating Factor toxicity, Granulocyte-Macrophage Colony-Stimulating Factor toxicity, Interleukin-3 toxicity, Leukemia, Myeloid drug therapy
- Abstract
The effect of stimulating acute myeloid leukemia blast cells with a combination of growth factors (G-CSF, GM-CSF, and IL-3) on cellular resistance to the antileukemia drugs Ara-C, daunorubicin, aclarubicin, and mitoxantrone was studied. For assessment of in vitro cellular drug resistance the MTT assay was employed. Stimulated cells showed enhanced sensitivity to Ara-C (p < 0.02), whereas a significant increase in cellular drug resistance to daunorubicin (p < 0.02) was observed. Variable and statistically non-significant changes in drug resistance to aclarubicin and mitoxantrone was induced by stimulation of the blast cells. We conclude on the basis of these observations that myeloid growth factors should be used with caution in combination with daunorubicin in AML treatment until further confirmatory evidence has been presented by other investigators.
- Published
- 1993
- Full Text
- View/download PDF